What is Apogee Therapeutics, Inc.'s depreciation?

Apogee Therapeutics, Inc. (APGE) reported depreciation of $408K in Q1 2026.

How has Apogee Therapeutics, Inc.'s depreciation changed year-over-year?

Apogee Therapeutics, Inc.'s depreciation increased by 97.1% year-over-year, from $207K to $408K.

Apogee Therapeutics, Inc. APGE Depreciation

Depreciation at other companies

AbbVieABBV

——

Immunovant, Inc.IMVT

——

Summit TherapeuticsSMMT

——

Ionis PharmaceuticalsIONS

——

Segments

By segment

See full

Reportable Segment Aggregation Before Other Operating$408K+97.1%

Other financials

Income statement

See full

Operating income-$82.8M-31.2%

Net income-$74.1M-33.9%

EPS (diluted)-$1.06-11.6%

Balance sheet

See full

Cash & equivalents$451.8M+323%

Total debt$8.0M-31.9%

Total assets$1.3B+81.1%

Cash flow

See full

Operating cash flow-$55.6M-14.6%

CapEx$62.0K—

Free cash flow-$62.8M+7.3%

Valuation

See full

Market cap$6.81B+189%

Enterprise value$6.37B+181%

Returns & leverage

See full

Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s depreciation?: Apogee Therapeutics, Inc. (APGE) reported depreciation of $408K in Q1 2026.
How has Apogee Therapeutics, Inc.'s depreciation changed year-over-year?: Apogee Therapeutics, Inc.'s depreciation increased by 97.1% year-over-year, from $207K to $408K.